v3.26.1
Collaboration Agreements - Narrative (Details)
1 Months Ended 3 Months Ended
Mar. 31, 2024
target
Mar. 31, 2026
USD ($)
extensionOption
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue from collaboration   $ 2,831,000 $ 4,658,000  
Long-term deferred revenue   $ 44,509,000   $ 44,509,000
Bristol Myers Squibb Company ("BMS") | Amended Collaboration Agreement 2019        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Agreement extension period, options to extend 2 years 1 year    
Number of gene targets | target 3      
Number of extension options, expired | extensionOption   1    
Revenue from collaboration   $ 0 $ 0  
Short-term deferred revenue   0   0
Long-term deferred revenue   $ 40,500,000   $ 40,500,000